search
Back to results

Natriuretic Effect of Telmisartan Versus Placebo in Patients With Mild-to-Moderate Hypertension

Primary Purpose

Hypertension

Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Telmisartan, low dose
Telmisartan, high dose
Placebo
Sponsored by
Boehringer Ingelheim
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Mild-to-moderate hypertension as defined by a morning mean diastolic blood pressure from ≥ 90 and ≤ 115 mmHg and a mean systolic blood pressure ≤ 200 mmHg after five minutes in the seated position at the end of three weeks of placebo run-in treatment
  • Male or female patients between 18 and 65 years of age, inclusive. Patients 60 to 65 years of age must have a screening 24-hour urine creatinine clearance rate of ≥ 1 mL/sec
  • Ability to provide written informed consent

Exclusion Criteria:

  • Pre-menopausal women (last menstruation ≤ one year to start of screening)
  • Post-menopausal women (last menstruation > one year from start of screening or have had a hysterectomy and oophorectomy)

    • Who have < three months of stable estrogen replacement therapy at screening
    • Who will be on progesterone therapy at any time during the trial
  • Known or suspected secondary hypertension
  • Hepatic and/or renal dysfunction as defined by the following laboratory parameters:

    • ALT (alanine aminotransferase) or AST (aspartate aminotransferase) greater than two times the upper limit of reference range
    • Serum creatinine greater than 2.3 mg/dL
  • Bilateral renal artery stenosis; renal artery stenosis in a solitary kidney; post-renal transplant
  • NYHA (New York Heart Association) functional class CHF (chronic heart failure) III-IV
  • Unstable angina, myocardial infarction or cardiac surgery within the preceding three months
  • Stroke within the preceding six months
  • PTCA (percutaneous transluminal coronary angioplasty) within the preceding three months
  • History of angioedema
  • Sustained ventricular tachycardia, atrial fibrillation, or other clinically relevant cardiac arrhythmias as determined by the clinical Investigator
  • Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant stenosis of aortic or mitral valve
  • Administration of digoxin or other digitalis-type drugs
  • Patients with insulin-dependent and non-insulin-dependent diabetes mellitus
  • History of drug or alcohol dependency
  • Use of antihypertensive agents such as diuretics, ACE inhibitors, angiotensin II antagonists, α-blockers, β-blockers, calcium channel antagonists, direct vasodilators at any time during the trial
  • Administration of other non-antihypertensive medications known to affect blood pressure (e.g., oral corticosteroids, MAO (monoamine oxidase) inhibitors, nitrates) at any time during the trial
  • Chronic administration of high doses of NSAIDS and aspirin (e.g., ibuprofen for rheumatoid arthritis and osteoarthritis in total daily dose in excess of 1600 mg, aspirin in excess of 2 Gm per day)
  • Chronic use of salt substitutes containing potassium chloride; potassium supplements; extreme dietary restrictions
  • Clinically significant sodium depletion as defined by a serum sodium level less than 130 mEq/L
  • Clinically significant hyperkalemia as defined by a serum potassium level greater than 6.0 mEq/L. Clinically significant hypokalemia as defined by a serum potassium level less than 3.0 mEq/L
  • Patients receiving any investigational therapy within one month of signing the informed consent form. Note that patients who have participated in previous telmisartan studies may participate in this study provided there has been at least one month between discontinuing the previous study and signing the consent for the present study
  • Known hypersensitivity to any component of telmisartan
  • Any other clinical condition which, in the opinion of the principal Investigator, would not allow safe completion of the protocol and safe administration of trial medication

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm Type

    Experimental

    Experimental

    Placebo Comparator

    Arm Label

    Telmisartan, low dose

    Telmisartan, high dose

    Placebo

    Arm Description

    3 weeks placebo run-in (normal diet), 1 week placebo run-in (controlled sodium diet), 2 weeks double-blind treatment ,1 week placebo wash-out (controlled sodium diet)

    3 weeks placebo run-in (normal diet), 1 week placebo run-in (controlled sodium diet), 2 weeks double-blind treatment, 1 week placebo wash-out (controlled sodium diet)

    3 weeks placebo run-in (normal diet), 1 week placebo run-in (controlled sodium diet), 2 weeks double-blind treatment, 1 week placebo wash-out (controlled sodium diet)

    Outcomes

    Primary Outcome Measures

    Cumulative urinary sodium loss

    Secondary Outcome Measures

    Cumulative urine sodium loss
    Changes in body weight
    Changes in plasma norepinephrine
    Changes in renin activity
    Changes in aldosterone
    Changes in urine potassium
    Changes in creatinine chloride
    Changes in bicarbonate
    Changes in uric acid
    Cumulative urinary sodium gain during wash-out period
    Changes in seated clinic blood pressure
    Changes in 24 hour ambulatory Blood Pressure (ABPM) after the first dose of telmisartan
    Number of patients with adverse events
    Number of patients with abnormal findings in physical examination
    Number of patients with abnormal findings in 12-lead electrocardiogram (ECG)
    Number of patients with abnormal changes in laboratory parameters

    Full Information

    First Posted
    June 26, 2014
    Last Updated
    July 7, 2014
    Sponsor
    Boehringer Ingelheim
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02176499
    Brief Title
    Natriuretic Effect of Telmisartan Versus Placebo in Patients With Mild-to-Moderate Hypertension
    Official Title
    Natriuretic Effect of Telmisartan Versus Placebo in Patients With Mild-to-Moderate Hypertension On a Controlled Sodium Diet (100 mmol/Day)
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    July 2014
    Overall Recruitment Status
    Completed
    Study Start Date
    February 1999 (undefined)
    Primary Completion Date
    July 1999 (Actual)
    Study Completion Date
    undefined (undefined)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Boehringer Ingelheim

    4. Oversight

    5. Study Description

    Brief Summary
    Study to compare the natriuretic effect of telmisartan to placebo in mild-to-moderate hypertensive patients on a controlled sodium diet as well as to explore the effects of telmisartan on norepinephrine, plasma renin activity (PRA), plasma aldosterone, urine potassium, creatinin, chloride, bicarbonate and uric acid excretion. Additionally it was assessed whether the natriuretic effect disappears after treatment when telmisartan is stopped. The effects of telmisartan on seated clinic blood pressure and the relationship between urine sodium loss and decrease in ambulatory blood pressure after the first dose were assessed descriptively. Assessment of safety was also considered.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Hypertension

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 3
    Interventional Study Model
    Parallel Assignment
    Masking
    Double
    Allocation
    Randomized
    Enrollment
    26 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Telmisartan, low dose
    Arm Type
    Experimental
    Arm Description
    3 weeks placebo run-in (normal diet), 1 week placebo run-in (controlled sodium diet), 2 weeks double-blind treatment ,1 week placebo wash-out (controlled sodium diet)
    Arm Title
    Telmisartan, high dose
    Arm Type
    Experimental
    Arm Description
    3 weeks placebo run-in (normal diet), 1 week placebo run-in (controlled sodium diet), 2 weeks double-blind treatment, 1 week placebo wash-out (controlled sodium diet)
    Arm Title
    Placebo
    Arm Type
    Placebo Comparator
    Arm Description
    3 weeks placebo run-in (normal diet), 1 week placebo run-in (controlled sodium diet), 2 weeks double-blind treatment, 1 week placebo wash-out (controlled sodium diet)
    Intervention Type
    Drug
    Intervention Name(s)
    Telmisartan, low dose
    Intervention Type
    Drug
    Intervention Name(s)
    Telmisartan, high dose
    Intervention Type
    Drug
    Intervention Name(s)
    Placebo
    Primary Outcome Measure Information:
    Title
    Cumulative urinary sodium loss
    Time Frame
    0-4, 4-8, 8-24 hours post-dose at baseline, day 0, day 7 and 0-24 hours post-dose on days 1-6
    Secondary Outcome Measure Information:
    Title
    Cumulative urine sodium loss
    Time Frame
    0-24 hours post-dose on days 8-13 and 0-4, 4-8, 8-24 hours post-dose on day 14
    Title
    Changes in body weight
    Time Frame
    24 hours post-dose on days -28, -21 to -14, -7, -1, 0, 7, 14 and 22
    Title
    Changes in plasma norepinephrine
    Time Frame
    Baseline, on day 0 after the end of the 24 hour dosing interval, on days 7, 14 and 22
    Title
    Changes in renin activity
    Time Frame
    Baseline, on day 0 after the end of the 24 hour dosing interval, on days 7, 14 and 22
    Title
    Changes in aldosterone
    Time Frame
    Baseline, on day 0 after the end of the 24 hour dosing interval, on days 7, 14 and 22
    Title
    Changes in urine potassium
    Time Frame
    Baseline, on day 0 after the end of the 24 hour dosing interval, on days 7, 14 and 22
    Title
    Changes in creatinine chloride
    Time Frame
    Baseline, on day 0 after the end of the 24 hour dosing interval, on days 7, 14 and 22
    Title
    Changes in bicarbonate
    Time Frame
    Baseline, on day 0 after the end of the 24 hour dosing interval, on days 7, 14 and 22
    Title
    Changes in uric acid
    Time Frame
    Baseline, on day 0 after the end of the 24 hour dosing interval, on days 7, 14 and 22
    Title
    Cumulative urinary sodium gain during wash-out period
    Time Frame
    0-24 hours post-dose on days from day 15 to 22
    Title
    Changes in seated clinic blood pressure
    Time Frame
    Baseline and day 14
    Title
    Changes in 24 hour ambulatory Blood Pressure (ABPM) after the first dose of telmisartan
    Time Frame
    Day 0
    Title
    Number of patients with adverse events
    Time Frame
    up to 50 days
    Title
    Number of patients with abnormal findings in physical examination
    Time Frame
    Baseline and day 22
    Title
    Number of patients with abnormal findings in 12-lead electrocardiogram (ECG)
    Time Frame
    Baseline and day 22
    Title
    Number of patients with abnormal changes in laboratory parameters
    Time Frame
    Baseline and day 22

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    65 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Mild-to-moderate hypertension as defined by a morning mean diastolic blood pressure from ≥ 90 and ≤ 115 mmHg and a mean systolic blood pressure ≤ 200 mmHg after five minutes in the seated position at the end of three weeks of placebo run-in treatment Male or female patients between 18 and 65 years of age, inclusive. Patients 60 to 65 years of age must have a screening 24-hour urine creatinine clearance rate of ≥ 1 mL/sec Ability to provide written informed consent Exclusion Criteria: Pre-menopausal women (last menstruation ≤ one year to start of screening) Post-menopausal women (last menstruation > one year from start of screening or have had a hysterectomy and oophorectomy) Who have < three months of stable estrogen replacement therapy at screening Who will be on progesterone therapy at any time during the trial Known or suspected secondary hypertension Hepatic and/or renal dysfunction as defined by the following laboratory parameters: ALT (alanine aminotransferase) or AST (aspartate aminotransferase) greater than two times the upper limit of reference range Serum creatinine greater than 2.3 mg/dL Bilateral renal artery stenosis; renal artery stenosis in a solitary kidney; post-renal transplant NYHA (New York Heart Association) functional class CHF (chronic heart failure) III-IV Unstable angina, myocardial infarction or cardiac surgery within the preceding three months Stroke within the preceding six months PTCA (percutaneous transluminal coronary angioplasty) within the preceding three months History of angioedema Sustained ventricular tachycardia, atrial fibrillation, or other clinically relevant cardiac arrhythmias as determined by the clinical Investigator Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant stenosis of aortic or mitral valve Administration of digoxin or other digitalis-type drugs Patients with insulin-dependent and non-insulin-dependent diabetes mellitus History of drug or alcohol dependency Use of antihypertensive agents such as diuretics, ACE inhibitors, angiotensin II antagonists, α-blockers, β-blockers, calcium channel antagonists, direct vasodilators at any time during the trial Administration of other non-antihypertensive medications known to affect blood pressure (e.g., oral corticosteroids, MAO (monoamine oxidase) inhibitors, nitrates) at any time during the trial Chronic administration of high doses of NSAIDS and aspirin (e.g., ibuprofen for rheumatoid arthritis and osteoarthritis in total daily dose in excess of 1600 mg, aspirin in excess of 2 Gm per day) Chronic use of salt substitutes containing potassium chloride; potassium supplements; extreme dietary restrictions Clinically significant sodium depletion as defined by a serum sodium level less than 130 mEq/L Clinically significant hyperkalemia as defined by a serum potassium level greater than 6.0 mEq/L. Clinically significant hypokalemia as defined by a serum potassium level less than 3.0 mEq/L Patients receiving any investigational therapy within one month of signing the informed consent form. Note that patients who have participated in previous telmisartan studies may participate in this study provided there has been at least one month between discontinuing the previous study and signing the consent for the present study Known hypersensitivity to any component of telmisartan Any other clinical condition which, in the opinion of the principal Investigator, would not allow safe completion of the protocol and safe administration of trial medication

    12. IPD Sharing Statement

    Links:
    URL
    http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/502/502.255_U00-3242.pdf
    Description
    Related Info

    Learn more about this trial

    Natriuretic Effect of Telmisartan Versus Placebo in Patients With Mild-to-Moderate Hypertension

    We'll reach out to this number within 24 hrs